Literature DB >> 21345787

Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.

Hatem Necib1, Camilo Garcia, Antoine Wagner, Bruno Vanderlinden, Patrick Emonts, Alain Hendlisz, Patrick Flamen, Irène Buvat.   

Abstract

UNLABELLED: In PET-based patient monitoring, metabolic tumor changes occurring between PET scans are most often assessed visually or by measuring only a few parameters (tumor volume or uptake), neglecting most of the image content. We propose and evaluate a parametric imaging (PI) method to assess tumor changes at the voxel level.
METHODS: Seventy-eight pairs of tumor images obtained from baseline and follow-up (18)F-FDG PET/CT for 28 patients with metastatic colorectal cancer were considered. For each pair, after CT-based registration of the PET volumes, the 2 PET datasets were subtracted. A biparametric graph of subtracted voxel values versus voxel values in the first PET scan was obtained. A model-based analysis of this graph was used to identify the tumor voxels in which significant changes occurred between the 2 scans and yielded indices characterizing these changes. The Response Evaluation Criteria in Solid Tumors (RECIST) based on the CT images obtained 5-8 wk after the second PET/CT scan were used to classify tumor masses as responding or progressive. On the basis of this classification, we compared the sensitivity and specificity of PI and an approach based on recommendations from the European Organization for Research and Treatment of Cancer (EORTC).
RESULTS: For tumor-based classification, the EORTC-based approach had a sensitivity and specificity of 85% and 52%, respectively, for detecting responding lesions, whereas PI had a sensitivity and specificity of 100% and 53%, respectively. None of responding tumors using RECIST was classified as progressive with the PI or EORTC-based criteria. Among the 14 progressive lesions according to RECIST, 12 were identified as progressive with PI whereas EORTC-based criteria classified only 1 as progressive and 13 as stable tumors. Considering the patient-based classification, none of the responders according to RECIST was classified as having progressive disease with the PI and EORTC-based criteria. PI has the advantage of showing a parametric image of the patient response to therapy, indicating potential heterogeneity in tumor response.
CONCLUSION: The PI method has been successfully applied to characterize early metabolic tumor changes in 78 lesions from (18)F-FDG PET/CT scans of patients with metastatic colorectal cancer during chemotherapy. The PI findings correlated well with the standard RECIST-based response assessment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21345787     DOI: 10.2967/jnumed.110.080150

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

Review 1.  The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach.

Authors:  Leonardo Patrlj; Mario Kopljar; Robert Kliček; Masa Hrelec Patrlj; Marijan Kolovrat; Mislav Rakić; Antonija Duzel
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 2.  Computerized PET/CT image analysis in the evaluation of tumour response to therapy.

Authors:  W Lu; J Wang; H H Zhang
Journal:  Br J Radiol       Date:  2015-02-27       Impact factor: 3.039

3.  Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.

Authors:  Mathieu Hatt; John A Lee; Charles R Schmidtlein; Issam El Naqa; Curtis Caldwell; Elisabetta De Bernardi; Wei Lu; Shiva Das; Xavier Geets; Vincent Gregoire; Robert Jeraj; Michael P MacManus; Osama R Mawlawi; Ursula Nestle; Andrei B Pugachev; Heiko Schöder; Tony Shepherd; Emiliano Spezi; Dimitris Visvikis; Habib Zaidi; Assen S Kirov
Journal:  Med Phys       Date:  2017-05-18       Impact factor: 4.071

4.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.

Authors:  Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-14       Impact factor: 9.236

5.  Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.

Authors:  Irène Buvat; Hatem Necib; Camilo Garcia; Antoine Wagner; Bruno Vanderlinden; Patrick Emonts; Alain Hendlisz; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-19       Impact factor: 9.236

6.  The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.

Authors:  René Adam; Aimery De Gramont; Joan Figueras; Ashley Guthrie; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Josep Tabernero; Catherine Teh; Eric Van Cutsem
Journal:  Oncologist       Date:  2012-09-07

7.  Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings.

Authors:  Virendra Kumar; Kavindra Nath; Claudia G Berman; Jongphil Kim; Tawee Tanvetyanon; Alberto A Chiappori; Robert A Gatenby; Robert J Gillies; Edward A Eikman
Journal:  Clin Nucl Med       Date:  2013-03       Impact factor: 7.794

8.  A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration.

Authors:  Maxine Tan; Zheng Li; Yuchen Qiu; Scott D McMeekin; Theresa C Thai; Kai Ding; Kathleen N Moore; Hong Liu; Bin Zheng
Journal:  IEEE Trans Med Imaging       Date:  2015-08-27       Impact factor: 10.048

9.  Predicting pathologic tumor response to chemoradiotherapy with histogram distances characterizing longitudinal changes in 18F-FDG uptake patterns.

Authors:  Shan Tan; Hao Zhang; Yongxue Zhang; Wengen Chen; Warren D D'Souza; Wei Lu
Journal:  Med Phys       Date:  2013-10       Impact factor: 4.071

Review 10.  State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET.

Authors:  Thomas Carlier; Clément Bailly
Journal:  Front Med (Lausanne)       Date:  2015-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.